Please assess the completion status of the following clinical trial:

Trial Title: CyberKnife® for Hepatic Metastases From Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female~* Hepatic metastases from histologically confirmed colorectal adenocarcinoma~* 3 hepatic lesions or less present~* Cumulative size of hepatic lesions between 1 and 10 cm~* Treatment determined by the liver/GI tumor board or equivalent organization at the participating site~* Metastatic disease not amenable to surgery as assessed by the panel (including a surgeon) or patient who refuses surgery~* Patient must be able to undergo contrast enhanced CT for planning~* Age \>= 18 years old~* Performance Status (ECOG) ≤ 2~* Minimum of 6 months between the initial diagnosis of the disease and the first hepatic metastasis~* Minimum of 4 weeks between prior chemotherapy or targeted therapy and the first CyberKnife session~* Total bilirubin ≤ 3 times the upper limit of normal, ASAT and ALAT ≤ 5 times the upper limit of normal~* Albumin \>= 36 g/L and lymphocytes \>= 700/mm3~* No contraindication to fiducials implantation, hemostasis problems shall be corrected before implantation~* Life expectancy \>= 3 months~* Patient affiliated with a health insurance system. Applicable for French patients only.~* Patient having signed the informed consent~Exclusion Criteria:~* Prior abdominal radiation therapy~* Any evidence of visible intra-hepatic bile duct dilatation on pre-treatment images~* Extrahepatic metastases~* Current evidence of ascitis~* Renal insufficiency (creatinine clearance \< 45 ml/min)~* Known allergy to gold~* Pregnant or lactating woman~* Prior history of other cancer except basocellular carcinoma and in situ cervix carcinoma~* Patient already enrolled in another therapeutic clinical trial~* Inability to comply with follow-up visits for geographical, social or psychological reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CyberKnife SBRT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).